These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8366978)
1. Dynamics of bone aluminum over one year of functioning renal graft. Bertolone G; Andriani M; Bonucci E; Ballanti P; Costantini S; Giordano R; Mattiello G; Calconi G; Maresca MC; Galardi N Nephron; 1993; 64(4):540-6. PubMed ID: 8366978 [TBL] [Abstract][Full Text] [Related]
2. Aluminum metabolism and bone histology after kidney transplantation: a one-year follow-up study. Nordal KP; Dahl E; Halse J; Aksnes L; Thomassen Y; Flatmark A J Clin Endocrinol Metab; 1992 May; 74(5):1140-5. PubMed ID: 1569161 [TBL] [Abstract][Full Text] [Related]
3. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ]. Jarava C; Armas JR; Palma A Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651 [TBL] [Abstract][Full Text] [Related]
4. The compartmentalization and metabolism of aluminum in uremic rats. Alfrey AC; Sedman A; Chan YL J Lab Clin Med; 1985 Feb; 105(2):227-33. PubMed ID: 3973462 [TBL] [Abstract][Full Text] [Related]
5. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Joffe P; Olsen F; Heaf JG; Gammelgaard B; Pödenphant J Clin Nephrol; 1989 Sep; 32(3):133-8. PubMed ID: 2791364 [TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of bone aluminum content and bone histology in patients on chronic hemodialysis and hemofiltration. Sebert JL; Fournier A; Leflon P; Fohrer P; de Frémont JF; Morinière P; Galy C; Marie A; Demontis R; Boudailliez B Nephron; 1986; 42(1):34-40. PubMed ID: 3941748 [TBL] [Abstract][Full Text] [Related]
7. Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease. Parisien M; Charhon SA; Arlot M; Mainetti E; Chavassieux P; Chapuy MC; Meunier PJ J Bone Miner Res; 1988 Jun; 3(3):259-67. PubMed ID: 3213621 [TBL] [Abstract][Full Text] [Related]
8. Bone aluminum and histomorphometric features of renal osteodystrophy. Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841 [TBL] [Abstract][Full Text] [Related]
9. Aluminium accumulates on inactive bone surfaces after parathyroidectomy in uremic rats. Vukicević S; Stavljenić A Horm Metab Res; 1989 Jan; 21(1):15-7. PubMed ID: 2925150 [TBL] [Abstract][Full Text] [Related]
10. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure. Malluche HH; Smith AJ; Abreo K; Faugere MC N Engl J Med; 1984 Jul; 311(3):140-4. PubMed ID: 6377067 [TBL] [Abstract][Full Text] [Related]
11. Aluminum deposition in the bone of patients with chronic renal failure--detection of aluminum accumulation without signs of aluminum toxicity in bone using acid solochrome azurine. Rüster M; Abendroth K; Lehmann G; Stein G Clin Nephrol; 2002 Oct; 58(4):305-12. PubMed ID: 12400847 [TBL] [Abstract][Full Text] [Related]
12. Reversal of aluminum-related bone disease after renal transplantation. David-Neto E; Jorgetti V; Soeiro NM; Pereira RC; Borelli A; Ianhez LE; Sabbaga E; Wajchemberg BL; Arap S Am J Nephrol; 1993; 13(1):12-7. PubMed ID: 8322836 [TBL] [Abstract][Full Text] [Related]
13. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine? Hodsman AB; Hood SA; Brown P; Cordy PE J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379 [TBL] [Abstract][Full Text] [Related]
14. Aluminum levels and stores in patients with total hip endoprostheses from TiAIV or TiAINb alloys. Dittert DD; Warnecke G; Willert HG Arch Orthop Trauma Surg; 1995; 114(3):133-6. PubMed ID: 7619633 [TBL] [Abstract][Full Text] [Related]
15. Uremic toxin and bone metabolism. Iwasaki Y; Yamato H; Nii-Kono T; Fujieda A; Uchida M; Hosokawa A; Motojima M; Fukagawa M J Bone Miner Metab; 2006; 24(2):172-5. PubMed ID: 16502128 [TBL] [Abstract][Full Text] [Related]
16. Vitamin D, desferrioxamine and aluminum-induced bone disease in uremic rats. Verbeelen D; Smeyers-Verbeke J; van Hooff I; de Roy G Nephron; 1989; 53(1):54-60. PubMed ID: 2779702 [TBL] [Abstract][Full Text] [Related]
17. Relationship of body iron status and serum aluminum in chronic renal insufficiency patients not taking any aluminum-containing drugs. Lin JL; Lim PS; Leu ML Am J Nephrol; 1995; 15(2):118-22. PubMed ID: 7733147 [TBL] [Abstract][Full Text] [Related]
18. Influence of biochemical and hormonal factors on the bone histomorphometric features of uraemic patients. Fournier A; Sebert JL; Fohrer P; Moriniere P; Lambrey G; Herve MA; Leflon P; Gueris J; Garabedian M Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():415-20. PubMed ID: 3991534 [TBL] [Abstract][Full Text] [Related]
19. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings. Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018 [TBL] [Abstract][Full Text] [Related]
20. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. Nordal KP; Dahl E J Clin Endocrinol Metab; 1988 Nov; 67(5):929-36. PubMed ID: 3182964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]